PacBio's SPRQ Chemistry: Revolutionizing Long-Read Sequencing and Cost-Effectiveness
Tuesday, Oct 29, 2024 9:11 am ET
1min read PacBio, a leading developer of high-quality, highly accurate sequencing solutions, has announced a significant breakthrough with the introduction of SPRQ chemistry for its Revio long-read sequencing system. This advancement reduces DNA input requirements by four-fold, enabling more sample types to be sequenced with HiFi sequencing technology. It also increases the Revio system's output, which, combined with improved analysis methods, enables customers to reduce their sequencing cost per genome by up to 50 percent. This article explores how these advancements contribute to the affordability and competitiveness of the Revio system in the long-read sequencing market.
The 4x reduction in DNA input requirements to 500ng per sample allows for the sequencing of a broader range of sample types, such as saliva extracted with PacBio's new Nanobind protocol and tumor samples. This expansion in sample types enables researchers to investigate a wider range of scientific applications and accelerate the pace of discovery.
The 33% increase in data output per SMRT Cell, paired with improved analysis methods, contributes to the overall cost reduction. This increase in data output enables each Revio instrument to sequence up to 2,500 human whole genomes per year at a cost of just under $500 per human genome. This affordability makes HiFi sequencing accessible to a broader range of research projects and institutions.
The improvements in methylation calling and the addition of new types of methylation marks expand the multiomics capabilities of the Revio system. The new DNA methylation callers provide improved accuracy for calling 5mC, making HiFi sequencing an attractive alternative to methylation arrays. Additionally, the new capability to call 6mA, a marker of open chromatin in the Fiber-seq assay, provides DNA, methylation, and chromatin accessibility all from a single DNA input and sequencing run.
These advancements in the Revio system contribute to its competitiveness in the long-read sequencing market. The reduced DNA input requirements, increased data output, and expanded multiomics capabilities enable researchers to explore a broader range of scientific applications and accelerate the pace of discovery. The affordability of the Revio system, with a cost per genome of less than $500, makes it an attractive option for researchers seeking high-quality, highly accurate sequencing solutions. As the demand for long-read sequencing continues to grow, PacBio's SPRQ chemistry and Revio system are poised to play a significant role in shaping the future of the sequencing market.
The 4x reduction in DNA input requirements to 500ng per sample allows for the sequencing of a broader range of sample types, such as saliva extracted with PacBio's new Nanobind protocol and tumor samples. This expansion in sample types enables researchers to investigate a wider range of scientific applications and accelerate the pace of discovery.
The 33% increase in data output per SMRT Cell, paired with improved analysis methods, contributes to the overall cost reduction. This increase in data output enables each Revio instrument to sequence up to 2,500 human whole genomes per year at a cost of just under $500 per human genome. This affordability makes HiFi sequencing accessible to a broader range of research projects and institutions.
The improvements in methylation calling and the addition of new types of methylation marks expand the multiomics capabilities of the Revio system. The new DNA methylation callers provide improved accuracy for calling 5mC, making HiFi sequencing an attractive alternative to methylation arrays. Additionally, the new capability to call 6mA, a marker of open chromatin in the Fiber-seq assay, provides DNA, methylation, and chromatin accessibility all from a single DNA input and sequencing run.
These advancements in the Revio system contribute to its competitiveness in the long-read sequencing market. The reduced DNA input requirements, increased data output, and expanded multiomics capabilities enable researchers to explore a broader range of scientific applications and accelerate the pace of discovery. The affordability of the Revio system, with a cost per genome of less than $500, makes it an attractive option for researchers seeking high-quality, highly accurate sequencing solutions. As the demand for long-read sequencing continues to grow, PacBio's SPRQ chemistry and Revio system are poised to play a significant role in shaping the future of the sequencing market.
